Elevated concentrations of C-reactive protein in subjects with Type 2 diabetes mellitus are moderately influenced by glycemic control

Journal of Endocrinological Investigation

Volumn 26, Issue 3, 2003, Pages 216-221

  Rodríguez Morán, Martha ^a   Guerrero Romero, F ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Acute phase response; C reactive protein; Inflammatory response; NIDDM; Serum glucose

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ACUTE PHASE RESPONSE; ADULT; ANAMNESIS; ARTICLE; BODY MASS; CLINICAL EXAMINATION; CONTROLLED STUDY; DATA ANALYSIS; DIABETES CONTROL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATORY DISEASE; LABORATORY TEST; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MICROPARTICLE ENZYME IMMUNOASSAY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

EID: 0038542983     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345160     Document Type: Article

References (29)

1. Pepys M.B. The acute phase response and C-reactive protein. In: Weatherall D.J., Ledingham J.G.G., Warrell D.A. (Eds.), Oxford Textbook of Medicine, ed 3. Oxford University Press, Oxford, 1995, p. 1527.
2. Hak A.E., Stehouwer C.D., Bots M.L., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 1999, 19: 1986-1991.
3. McMillan D.E. Increased levels of acute-phase serum proteins in diabetes. Metabolism 1989, 38: 1042-1046.
4. Pickup J.C., Crook M.A. Is Type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998, 41: 1241-1248.
5. Pietropaolo M., Barinas-Mitchell E., Pietropaolo S.L., Kuller L.H., Trucco M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 2000, 49: 32-38.
6. Ford E.S. Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care 1999, 22: 1971-1977.
7. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40: 1286-1292.
8. Barzilay J.I., Abraham L., Heckbert S.R., et al. The relation of markers of inflammation to the development of glucose disorders in the elderly. The cardiovascular health study. Diabetes 2001, 50: 2384-2389.
9. Rodríguez-Morán M., Guerrero-Romero F. Increased levels of C-reactive protein in non-controlled type 2 diabetic subjects. J. Diabetes Complications 1999, 13: 211-215.
10. Subsecretaria de Prevención Control de Enfermedades, Coordinación de Vigilancia Epidemiológica. Norma Oficial Mexicana NOM-015-SSA2-1994, para la Prevención, Tratamiento y Control de la Diabetes. Secretaría de Salud, México 2000; p. 15.
11. Hutchinson W., Koenig W., Frölich M., Sund M., Lowe G., Pepys M.B. Immunoradiometric assay of circulating C-reactive protein: Age related values in the adult general population. Clin Chem 2000, 46: 934-938.
12. Macy E., Hayes T.E., Tracy R.P. Variability in the measurements of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clin Chem 1997, 43: 52-58.
13. Ebeling P., Teppo A.M., Koistinen H.A., Koivisto V.A. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metabolism 2001, 50: 283-287.
14. Yudkin J.S., Panahloo A., et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 2000, 43: 1099-1106.
15. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno-hypothesis. Diabetologia 1989, 32: 219-226.
16. Stephens J.M., Butts M.D., Pekala P.H. Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumor necrosis factor-alpha. J. Mol. Endocrinol. 1992, 9: 61-72.
17. Yudkin J.S., Stehouwer C.D.A., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role of cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 1999, 19: 972-978.
18. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995, 95: 2409-2415.
19. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N., for the MRFIT Research Group. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am. J. Epidemiol. 1996, 144: 537-547.
20. Tracy R.P., Psaty B.M., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler. Thromb. Vasc. Biol. 1997, 17: 2167-2176.
21. Koenig W., Sund M., Frölich M., et al. C-reactive protein, a sensitive marker of inflammation predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort Study, 1984 to 1992. Circulation 1999, 99: 237-242.
22. Hak E.A.E., Stehouwer C.D.A., Bots M.L., et al. Associations of C-reactive protein which measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 1999, 19: 1986-1991.
23. Lemieux I., Pascot A., Prud'homme D., et al. Atherosclerosis and lipoproteins. Elevated C-reactive protein. Another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 2001, 21: 961-968.
24. Festa A., D'Agostino Jr R., Howard G., Mykkäenen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102: 42-47.
25. Patel P., Mendall M.A., Carrington D., et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk. B.M.J. 1995, 311: 711-714.
26. Libby P., Rgan D., Skarlatos S. Roles of infectious agents in atherosclerosis and estenosis. An assessment of the evidence and need for future research. Circulation 1997; 96: 4095-4103.
27. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000, 342: 836-843.
28. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997, 336: 973-979.
29. Dandona P., Aljada A., Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: A new paradigm. Diabetologia 2002, 45: 924-930.